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ABSTRACT
Mesothelioma of the tunica vaginalis testis (MTVT) is a rare tumor that usually 
affects patients after the sixth decade of life. Exposure to asbestos is a known 
risk factor. Enlargement of the scrotal volume is the most common initial clinical 
manifestation, and about 15% of cases present metastasis at diagnosis. The 
treatment relies on surgical resection while the role of adjuvant chemotherapy 
and radiotherapy remains unclear. The prognosis for patients is generally 
poor, with a lethal outcome in 30% over a 24-month period. The authors report 
a case of a 62-year-old patient with the diagnosis of MTVT without a history 
of asbestos exposure. After surgical treatment, metastatic disease ensued. 
Chemotherapy was initiated, but could not be continued due to marked and 
fast clinical deterioration. The authors call attention to the difficulty of early 
diagnosis of MTVT due to a nonspecific clinical picture, the lack of action by the 
patient when the scrotal enlargement was first noticed, and the lack of tumor 
markers. Delayed diagnosis is definitely related to unfavorable prognosis.
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CASE REPORT
A 62-year-old man sought the Urology 
Department complaining of progressive 
enlargement of the left testicle during the last 12 
months associated with 5 kg of weight loss (7.3% 
of total body weight). He denied fever, testicular 
pain, or other local inflammatory sign. His past 
medical history included hypertension and diabetes 
mellitus. He had been a smoker of 20 packs/year 
but was abstinent for years. There was no reported 
history of cancer in his family; neither was there an 
occupation related to asbestos exposure.
The physical examination was normal except 
for thickening of the scrotal skin accompanied 
by left testicle enlargement. Neither hernias nor 
lymphadenopathy were present bilaterally in the 
inguinal region.
An ultrasonogram revealed a mild hydrocele 
on the right scrotal sac, and a heterogeneous 
testicular mass interspersed with some cystic areas 
on the left. The tumor measured 11.6 × 9.5 × 6.8 cm 
(Figure 1).
Serum chorionic gonadotropin was <3 IU/L 
(reference value [RV] for men <3 IU/L), alpha-
fetoprotein was 2.5 ng/mL (RV: <10 ng/mL) and lactic 
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areas. The tumoral infiltration spread to testicular 
parenchyma, rete testis, epididymis, tunica vaginalis 
and albuginea and spermatic cord. Angiolymphatic 
infiltration was present as well as intratumoral 
necrosis.
dehydrogenase was 310 U/L (RV: 240-480 U/L). 
Complementary laboratory workup was normal. 
Abdominal computed tomography (CT) showed a 
single periaortic lymph node, which measured 2.8 
cm at its longest axis.
An uneventful inguinal left orchiectomy 
was performed 10 days after the first visit. The left 
testicle and part of the scrotal sac, weighting 430 g 
and measuring 13,5 × 8,5 × 7,0 cm constituted the 
surgical specimen. At cut surface, a tumoral mass, 
of firm consistency, predominantly paratesticular 
involved the testicle and the spermatic cord, 
displacing them inferiorly. The epididymis was non-
identified (Figure 2).
The morphological features (Figure 3), 
associated to the Immunohistochemical panel 
(Table 1) were compatible with the diagnosis of 
biphasic (epithelioid and sarcomatoid) malignant 
paratesticular mesothelioma with desmoplasic 
Figure 1 – A and B – Ultrasonography of the left scrotal sac showing a heterogeneous mass with some 
scattered cystic areas (notedly in B).
Figure 2 – Gross view of the surgical specimen showing in: A – longitudinal section of left testicle and scrotal 
sac showing paratesticular tumor involving the testicle with fascicular areas, and in B – in detail, infiltration of 
testicular parenchyma in an area of discontinuity of the tunica albuginea.
Table 1 – Immunohistochemical panel
Antigen Result Antigen Result
Calretinin Positive P53 Positive
Vimentin Positive P63 Negative
Citokeratin 5 Positive BerEp4 Negative
WT-1 Positive CEA Negative
CA125 Positive MOC-31 Negative
D2-40 Positive P16 Negative
Ki 67 High index CD138 Negative
CA125 = cancer antigen 125; CEA = carcinoembryonic antigen; 
WT-1 = Wilms tumor protein
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DISCUSSION
Malignant mesotheliomas are uncommon 
tumors, mostly involving the pleura, peritoneum, or 
pericardium, but rarely originating from the tunica 
vaginalis testis.1 In 1957, Barbera and Rubino2 
described the first case of mesothelioma of the 
tunica vaginalis testis (MTVT), and since then, fewer 
than 230 cases have been reported.1,3 However, the 
first description of MTVT associated with asbestos 
was held by Fligiel and Kaneko in 1976.4 MTVT 
might be considered to be a variation of peritoneal 
mesothelioma, since the peritoneal lining extends 
into the scrotal sac.3,5 Since the description of 
Fligiel and Kaneko4 the association of MTVT and 
asbestos exposure has been widely reported.6-11 
This association was noted to occur between 34% 
and 42% of the cases,8,9 although this is considered 
to be underestimated because of insufficient clinical 
information. The failure of a patient to report a history 
of asbestos exposure does not necessarily mean 
that no exposure occurred as many individuals 
may not know that they have been exposed in the 
workplace or in the community.3 According to some 
studies, family exposure to asbestos increases the 
The patient was referred to the clinical 
oncology department for post-surgery follow-up. 
After 3 months, he complained of pain and bulging 
in the left groin. A physical examination revealed an 
enlarged inguinal lymph node measuring 8 × 4 cm. 
Abdominal, thoracic, and pelvic CT showed multiple 
and confluent enlarged lymph nodes in the posterior 
mediastinum, retrocrural space, periaortic, along the 
left gonadal vein, iliac chains, and in the left groin. 
The largest lymph node measured 10 × 6.4 cm. 
An impairment of concentration and elimination of 
intravenous contrast by the left kidney accompanied 
by moderate hydronephrosis were found, as well as 
a few non-calcified pulmonary nodules scattered 
bilaterally with up to 1.1 cm in the superior segment 
of the right lower lobe (Figure 4).
The patient received two cycles of 
chemotherapy, which included pemetrexed and 
cisplatin. After 20 days, he returned with a marked 
decline in performance status, complaining of 
weakness and intense abdominal pain due to 
the progression of the disease. Considering this 
scenario, he was referred to exclusive palliative 
care and died after 24 days.
Figure 3 – Photomicrography of the surgical specimen (paratesticular tumor) showing: in A – stromal infiltration 
by solid tumor with epithelioid pattern (HE, 200X); B – infiltration by sarcomatoid spindle cells (HE,200X); 
C – immunohistochemical positive reaction for calretinin (400X); D – immunohistochemical positive reaction 
for WT-1 (400X).
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hypotheses implicated in the oncogenesis of 
mesothelioma.13-15
Contrary to the usual pleural and peritoneal 
sites, the paratesticular disease is rare, and 
corresponds to 0.3-1.4% of all cases of malignant 
mesothelioma.1 Simultaneous involvement of other 
serosas has already been reported.16-18
MTVT may occur in a wide range of ages. 
Although 10% of cases occur in patients under 25 
years old, including children,9,19 the higher incidence 
mostly affects patients between the sixth and eighth 
decades of life.1
risk of pleural mesothelioma by 10 times.12 The 
frequency of exposure to asbestos among patients 
with MTVT is comparable to patients with pleural 
mesothelioma.8 Although asbestos exposure or 
contact with asbestos-containing material remain 
the only plausible risk factor, other studies suggest 
that hydrocele and trauma may also be risk factors 
for the development of MTVT.5 It is well known 
that there is a high coincidence rate between 
mesothelioma and hydrocele; some investigators 
consider it debatable whether hydrocele plays a role 
in the development of mesothelioma or vice versa.5 
Radiation or radiotherapy, viral infections, and 
chromosomal abnormalities are also speculative 
Figure 4 – Abdominal CT. A – Coronal reformation showing a heterogeneous mass involving the aorta and 
left iliac artery; B – Axial plane showing periaortic lymph nodes, delayed concentration/excretion of the 
contrast, and slight hydronephrosis; C – Axial plane showing lymph nodes conglomerate with signs of central 
necrosis along the left iliac artery; D – axial plane – multiple bilateral enlarged inguinal lymph nodes.
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MTVT is locally invasive in 40% of cases while 
15% present as metastatic disease at diagnosis.1 
Metastases occur via lymphatics—most commonly 
to the inguinal and periaortic lymph nodes, while 
the liver and lungs are frequently involved via 
hematogenous metastatic dissemination.1 The 
presence of lymph node involvement at diagnosis 
relates to the worst prognosis. Advanced age at 
diagnosis also represents a significantly worse 
prognosis and is related to the aggressive course 
of the disease.9,30,31 Tumor recurrence occurs in 
more than 60% of cases over the first 2 years from 
diagnosis and in more than 90% of cases over the 
first 5 years from diagnosis.30 The final lethal course 
is observed in 30% of cases after a median survival 
of 24 months.1
A clinical examination and CT scan should 
be performed every 3 months for 2 years as the 
recommended strategy for routine clinical care after 
curative treatment.32
Treatment of MTVT is based on inguinal 
radical orchiectomy concomitantly with inguinal or 
periaortic lymphadenectomy.1 In the cases where 
surgical access violates the scrotal skin, radiotherapy 
is recommended after surgery. In metastatic or 
advanced disease, palliative chemotherapy may 
reduce tumor volume and seems to play a role in 
the survival of patients for up to 10 months.32
Due to the scarcity of cases, treatment 
protocols rely on small series or case reports. 
Chemotherapy regimens are analogous to that used 
in pleural mesothelioma.33 Plas et al.9 showed a better 
response in patients with metastatic disease using 
radiotherapy combined with chemotherapy when 
compared with chemotherapy alone. Radiotherapy 
should be considered in patients with local disease 
after tumor-free margin extensive resection and 
patients with disseminated disease with a good 
clinical condition.34 In general, younger patients and 
early diagnosis are related to better prognosis.9 The 
role of adjuvant chemotherapy and radiotherapy 
is still controversial and requires further studies. 
Sebbag et al.35 reported two cases of MTVT. One 
was a disseminated intra-abdominal disease, which 
underwent tumor resection plus peritonectomy 
and intraperitoneal chemotherapy with cisplatin, 
obtaining a disease-free survival of 5 years. The 
other case referred to a local disease treated with 
adjuvant chemotherapy with doxorubicin, obtaining 
a survival of 24 months.
The most frequent clinical manifestation 
of MTVT is a rapidly-growing hydrocele (56.3%) 
and a paratesticular mass (32.8%).1 Both signs 
may present concomitantly, but that is not the 
rule.1 The testis of both sides are equally affected, 
and bilateral tunical involvement is exceptional.20 
When the hydrocele is the presenting sign, the 
paratesticular tumor is frequently overlooked. The 
lack of specific clinical features, as well as tumor 
markers, is responsible for the delayed definitive 
diagnosis, which constitutes the paramount problem 
of malignant MTVT. The diagnosis is usually raised 
during surgical resection by the intraoperative finding 
of hemorrhagic hydrocele and the presence of small 
nodules in the tunica vaginalis, but confirmation is 
only achieved with the histology.1 Clinical staging is 
usually performed with thoracic and abdominal CT. 
Positron emission tomography (PET) can be used, 
based on its reasonable accuracy to detect extra 
thoracic involvement in pleural mesothelioma.21,22
Morphologically, paratesticular meso-
theliomas are identical to mesotheliomas arising at 
other body parts and is comprised of three histological 
subtypes, namely: epithelial, which corresponds 
to about 70% of cases; biphasic, 27% of cases; 
and sarcomatous, 3% of cases.23 Three different 
architectural patterns can be observed. Papillary 
or tubulo-papillary are the two most common. Well-
differentiated patterns present a favorable prognosis 
and resemble a tumor arising from the intra-
abdominal peritoneum of young females. Besides, 
the absence of stromal infiltration and necrosis are 
also favorable morphology features.24 The third, and 
least frequent pattern, is multicystic mesothelioma, 
which shows a well-differentiated morphology. 
Multicystic mesothelioma is associated with large 
masses and is characterized as a favorable pattern 
in terms of prognosis.25
The immunohistochemical profile of this 
neoplasm includes positivity for cytokeratin 7 and 
5/6, calretinin, EMA, D2-40, and thrombomodulin, 
and negativity for cytokeratin 20, BerEP4, B72.3, 
MOC-31, and Leu-M1.26,27 More recently it has 
been shown that tunical mesothelioma express 
positivity for WT1 and CD138;28 it is well known 
that the former is expressed by mesotheliomas of 
other sites, and the latter—although not routinely 
studied—is potentially helpful in target therapy.1 
Vimentin varies from negative to diffusely positive 
according to its sarcomatous component.1 Positivity 
for calretinin differentiates mesothelioma from 
adenocarcinoma, and the negativity for BerEP4 
stands for mesothelioma versus adenocarcinoma.29 
50
Autopsy and Case Reports 2014; 4(1): 45-51 Fonseca LG, Marques DF, Takahashi TK, Aguiar FN, Ravanini JN, Saragiotto DF.
9. Plas E, RiedI CR, Pfluger H. Malignant mesothelioma 
of the tunica vaginalis testis. Review of the literature 
and assessment of prognostic parameters. Cancer. 
1998;83:2437-46. http://dx.doi.org/10.1002/(SICI)1097-
0142(19981215)83:12<2437::AID-CNCR6>3.0.CO;2-G
10. Attanoos RL, Gibbs AR. Primary malignant gonadal 
mesotheliomas and asbestos. Histopathology. 2000; 37:150-
9. http://dx.doi.org/10.1046/j.1365-2559.2000.00942.x
11. Perez-Ordonez B, Srigley JR. Mesothelial lesions of the 
paratesticular region. Semin Diagn Pathol. 2000;17:294-306.
12. Begin R. Asbestos exposure and pleuropulmonary cancer. 
Rev Mal Respir. 1998;15:723-30.
13. Peterson JT, Greenberg SD, Buffler PA. Non-asbestos-related 
malignant mesothelioma. Cancer. 1984;54:951-60. http://
dx.doi.org/10.1002/1097-0142(19840901)54:5<951::AID-
CNCR2820540536>3.0.CO;2-A
14. Taguchi T, Jhanwar S, Siegfried J, Keller SM, Testa JR. 
Recurrent deletions of specific chromosomal sites in 1p, 
3q, 6q and 9q in human malignant mesothelioma. Cancer. 
1993;53:4349-55.
15. Stenton SC. Asbestos, Simian virus 40 and malignant 
mesothelioma. Thorax. 1996;51:1074-6.
16. Ascoli V, Facciolo F, Rahimi S, Scalzo CC, Nardi F. 
Concomitant malignant mesothelioma of the pleura, 
peritoneum, and tunica vaginalis testis. Diagn Cytopathol. 
1996;14:243-8. http://dx.doi.org/10.1002/(SICI)1097-
0339(199604)14:3<243::AID-DC9>3.0.CO;2-I
17. Poggi A, Longo F, Mansueto G, et al. A case of mesothelioma 
of the tunica vaginalis testis, with involvement of the pleura 
and-peritoneum. Tumori. 2000;86:256-7.
18. Müller M, Stöckle M, Pecqueux JC, et al. Coincident 
manifestation of mesotheliomas of the tunica vaginalis 
and pleura. Case report and literature overview. Urologe A. 
2008; 47:200-4. http://dx.doi.org/10.1007/s00120-007-1576-2
19. Antman K, Cohen S, Dimitrov NV, Green M, Muggia F. 
Malignant mesothelioma of the tunica vaginalis testis. J 
Clin Oncol. 1984;2:447-51.
20. Pelzer A, Akkad T, Herwig R, et al. Synchronous bilateral 
malignant mesothelioma of tunica vaginalis testis: early 
diagnosis. Urology. 2004;64:1031. http://dx.doi.org/10.1016/j.
urology.2004.06.003
21. Sørensen JB, Ravn J, Loft A, Brenøe J, Berthelsen AK; 
Nordic Mesothelioma Group. Preoperative staging of 
mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron 
emission tomography/computed tomography fused imaging 
and mediastinoscopy compared to pathological findings after 
extrapleural pneumonectomy. Eur J Cardiothorac Surg. 2008; 
34:1090-6. http://dx.doi.org/10.1016/j.ejcts.2008.07.050
22. Wilcox BE, Subramaniam RM, Peller PJ, et al. Utility 
of integrated computed tomography-positron emission 
CONCLUSION
In the case reported herein, we could not 
evidence exposure to known risk factors, but the 
age and clinical presentation fit the reported MTVT 
clinical features. The long time between the onset 
of symptoms and the demand for medical attention 
is noteworthy, as well as the progressive and fast 
metastatic spreading after surgical treatment of an 
apparent local disease. Despite the rare occurrence, 
this tumor should be considered a differential 
diagnosis of mass or increase of scrotal volume, 
even if the first diagnosis is a hydrocele, regardless 
of a history of asbestos exposure or history of cancer 
in the family. Early diagnosis is of great importance 
for successful treatment and improved survival.
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